

# PEI Pharmacare Bulletin

Issue (2022 - 6)

June 1, 2022

## NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (EFFECTIVE DATE: JUNE 1, 2022)

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
Glucagon	Baqsimi	3 mg	Nasal Spray	02492415	LIL
Criteria	<p>Open benefit for up to 2 devices per 12 months for clients on insulin therapy. For quantities beyond this, a Special Authorization will have to be submitted:</p> <ul style="list-style-type: none"> <li>• The client will need to meet the following criteria: <ul style="list-style-type: none"> <li>○ For the treatment of severe hypoglycemia (SH) reactions in patients with diabetes mellitus receiving insulin and at high risk for SH, when impaired consciousness precludes oral carbohydrate administration.</li> </ul> </li> <li>• Request should detail the clinical need for greater than 2 glucagon devices per 12 months, including the number of devices anticipated</li> <li>• Request must be from a medical practitioner or nurse practitioner</li> <li>• Special authorization requests for additional doses will be considered for up to one device per month</li> <li>• SA is valid for 12 months</li> <li>• Coverage is limited to one unit at a time</li> </ul>				
Program Eligibility	Diabetes Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, Catastrophic Drug Program				

### Effective June 1, 2022, currently listed Glucagon devices will be eligible in the following manner:

- Coverage will be in the Diabetes Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, and Catastrophic Drug program
- The devices will be eligible as a regular benefit for up to two dispenses (one device per dispense) in a 12 month period for clients on insulin therapy
- If more than two devices are required in a 12 month period, a Special Authorization will have to be submitted, and the client meet the following criteria;
  - For the treatment of severe hypoglycemia (SH) reactions in patients with diabetes mellitus receiving insulin and at high risk for SH, when impaired consciousness precludes oral carbohydrate administration.
  - Request should detail the clinical need for greater than 2 glucagon devices per 12 months, including the number of devices anticipated
  - Request must be from a medical practitioner or nurse practitioner
  - Special authorization requests for additional doses will be considered for up to one device per month
  - SA is valid for 12 months
- Coverage is limited to one unit at a time
- The copay in the Diabetes Drug Program will be \$20 per device

- In addition to Baqsimi identified above, eligible devices include Glucagon Kit DIN 02243297, Glucagen Kit DIN 02333627, and Glucagen Vial DIN 0233619

**REMINDER: TWO NEW PROGRAMS EFFECTIVE JUNE 1ST:**

- **Substance Use Harm Reduction Drug Program**

- Please see:
  - “Pharmacist Bulletin - May 2022 (extra)”
  - <https://www.princeedwardisland.ca/en/information/health-pej/substance-use-harm-reduction-drug-program>

- **Diabetes Glucose Sensor Program**

- Please see Appendix F in the Formulary for a list of eligible glucose sensor supplies
- This program is administered by the Provincial Diabetes Program and any questions related to registration, coverage, or billing issues should be directed to:
  - Glucose Sensor Program / Insulin Pump Program
  - 16 Garfield Street
  - Charlottetown, PE C1A 6A5
  - Telephone: (902) 213-4825 or 1-833-335-0538 (toll free)
  - Email: [diabetesadminofficer@ihis.org](mailto:diabetesadminofficer@ihis.org)